Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects

Vista sencilla de ítem
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorDiethelm-Varela, Benjamín
dc.contributor.authorPavez, Valentina
dc.contributor.authorBerríos-Rojas, Roslye
dc.contributor.authorMéndez, Constanza
dc.contributor.authorRiedel, Claudia A.
dc.contributor.authorWhite, Jessica A.
dc.contributor.authorKalergis, Alexis M.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorGonzález, Pablo A.
dc.date.accessioned2023-12-06T17:29:41Z
dc.date.available2023-12-06T17:29:41Z
dc.date.issued2023-10-01
dc.descriptionINDEXACIÓN: SCOPUS.es
dc.description.abstractBackground: We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection. Methods: Serum samples obtained from volunteers immunized with CoronaVac (2 and 3 doses), breakthrough case patients, and from convalescent individuals were analyzed to determine the immunoglobulin (Ig) G responses against 3 structural and 8 nonstructural SARS-CoV-2 antigens. Results: Immunization with CoronaVac induced higher levels of antibodies against the viral membrane (M) protein compared with convalescent subjects both after primary vaccination and after a booster dose. Individuals receiving a booster dose displayed equivalent levels of IgG antibodies against the nucleocapsid (N) protein, similar to convalescent subjects. Breakthrough case patients produced the highest antibody levels against the N and M proteins. Antibodies against nonstructural viral proteins were present in >50% of the convalescent subjects. Conclusions: Vaccinated individuals elicited a different humoral response compared to convalescent subjects. The analysis of particular SARS-CoV-2 antigens could be used as biomarkers for determining infection in subjects previously vaccinated with CoronaVac. © 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.es
dc.identifier.citationJournal of Infectious Diseases, Volume 228, Issue 7, Pages 857 - 867, 1 October 2023es
dc.identifier.doi10.1093/infdis/jiad320
dc.identifier.issn00221899
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/54456
dc.language.isoenes
dc.publisherOxford University Presses
dc.rights.licenseCC BY 4.0 DEED Attribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectantibody responseses
dc.subjectbreakthroughes
dc.subjectCoronaVaces
dc.subjectSARS-CoV-2es
dc.subjectvaccinationes
dc.titleDifferential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjectses
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
jiad320.pdf
Tamaño:
4.15 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista